A phase II study of Gefinitib, an Egfr tyrosine kinase inhibitor, in second-line treatment of advanced esophageal cancer, reported that a significantly higher disease control rate (response plus stable disease) was observed in patients with ESCC histology or with high Egfr expression[42]. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.